Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,222 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Asthma
Interventions: Fluticasone Propionate; Drug
Lead sponsor: Dey; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Common Warts
Interventions: 10% EISO, Placebo, 20% EISO, 30% EISO; Drug
Lead sponsor: ViroXis Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Rogers, Arkansas • Fremont, California • Lomita, California + 17 more

Conditions: Hemophilia A, Hemophilia B
Interventions: ALN-AT3SC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Blood Sample; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Generalized Pustular Psoriasis
Interventions: Imsidolimab; Biological
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Encino, California • Largo, Florida • Miami, Florida + 2 more

Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 8
States / cities: Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Bordetella Infections, Bordetella Pertussis Infection, Bordetella Parapertussis Infection
Interventions: ARIES Bordetella Assay; Device
Lead sponsor: Luminex Molecular Diagnostics; Industry
Eligibility: Not listed
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 5
States / cities: Indianapolis, Indiana • Grosse Pointe Woods, Michigan • Albuquerque, New Mexico + 2 more

Conditions: Meningococcal Disease
Interventions: MenABCWY, Placebo, MenACWY; Biological · Other
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Obesity, Overweight
Interventions: Youth Soccer; Procedure
Lead sponsor: Leach Chiropractic Clinic; Other
Eligibility: 9 Years to 12 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Starkville, Mississippi

Conditions: ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Pembrolizumab, Radiation Therapy; Biological · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Juvenile Idiopathic Arthritis
Interventions: CNTO 148 (Golimumab), Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more

Conditions: Cellular Diagnosis, Prostate Cancer
Interventions: ClariCore Optical Biopsy System; Device
Lead sponsor: Precision Biopsy, Inc.; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Denver, Colorado • Baltimore, Maryland • New York, New York + 2 more

Conditions: Atopic Disease (Including Allergic Conjunctivitis)
Interventions: Drug: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Diabetic Foot, Diabetic Foot Ulcer, Ulcer Foot
Interventions: Human Autologous Homologous Skin Construct, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: PolarityTE; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Martinsville, Virginia

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate, Medication Event Monitoring System (MEMS), Adherence counseling; Drug · Device · Behavioral
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 29
States / cities: Homewood, Alabama • Pheonix, Arizona • Carlsbad, California + 26 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: PI3K-beta Inhibitor GSK2636771; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prader Willi Syndrome, Childhood Obesity
Interventions: Active Play at Home; Behavioral
Lead sponsor: California State University, Fullerton; Other
Eligibility: 8 Years to 15 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Fullerton, California • Gainesville, Florida

Conditions: Multiple Sclerosis
Interventions: Active tDCS, sham tDCS; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Covid19, Outcome, Fatal, Respiratory Failure, Acute Kidney Injury, Inflammation
Interventions: SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 4,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson's Disease
Interventions: Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa; Drug
Lead sponsor: Novartis; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 21
States / cities: Phoenix, Arizona • Aliso Viejo, California • Irvine, California + 17 more

Conditions: Presbyopia
Interventions: CSF-1, Vehicle; Drug
Lead sponsor: Orasis Pharmaceuticals Ltd.; Industry
Eligibility: 40 Years to 64 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 12
States / cities: Newport Beach, California • Petaluma, California • Colorado Springs, Colorado + 9 more

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obstructive Apnea
Interventions: Portable oxygen concentrator Inogen G5 model; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alzheimer Disease
Interventions: galantamine, BMS-708163; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

12-Week Study in Adult Subjects With Asthma

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

T Cell Profiling in Patients With Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Nutrition and Soccer for Pediatric Overweight and Obesity

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

SkinTE™ in the Treatment of Diabetic Foot Wounds

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study

tDCS for the Management of Multiple Sclerosis Related Fatigue

International Study of Inflammation in COVID-19

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

Comparison of a Demand Oxygen Delivery

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)